Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Combination therapies are superior to monotherapy for many cancers. This advantage was
historically ascribed to the ability of combinations to address tumor heterogeneity, but …

Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …

Focal adhesion kinase (FAK) is both a non-receptor tyrosine kinase and an adaptor protein
that primarily regulates adhesion signalling and cell migration, but FAK can also promote …

Melanoma brain metastasis (MBM) frequently occurs in patients with advanced melanoma;
yet, our understanding of the underlying salient biology is rudimentary. Here, we performed …

Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug
treatment and constitute a major cause of treatment failure. These cells are characterized by …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

Many patients with advanced cancers achieve dramatic responses to a panoply of
therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse …

Malignant transformation can result in melanoma cells that resemble different stages of their
embryonic development. Our gene expression analysis of human melanoma cell lines and …